Ranibizumab (lucentis) injection by anterior chamber in aphakic eyes with myopic choroidal neovascularization

purpose. macular choroidal neovascularization (CNV) is one of the most vision-threatening complications of myopia, which can lead to severe vision loss. Our purpose was to evaluate the safety and efficacy of trans-corneal injection of ranibizumab in the treatment of myopic CNV in aphakic patients. Materials and Methods. ten eyes of 10 aphakic patients with CNV secondary to pathologic myopia treated with three trans- corneal injection of ranibizumab were evaluated. A complete ophthalmologic examination including best-corrected visual acuity (BCVA) and fundus biomicroscopy, specular microscopy, fundus optical coherence tomography (OCT), fluorescein an- giography (FA) were performed at baseline and monthly for all patients. Mean time of follow-up was 6 months. results. The mean axial length was 27,6 mm (range, 25.7-31.3 mm). The mean initial visual acuity (VA) was 0.19 (decimal equivalent). A statistically significant improvement to a mean VA of 0.33 decimal equivalent (log-MAR:0.48) was demon- strated at the final follow-up. VA improved by a mean of 2.86 lines. Mean central macular thickness (CMT) measured with OCT was 340 μm (range, 179-663 μm) at the baseline, and was reduced significantly at the final follow-up to 212μm (range, 125-455 μm). No injection complications or drug-related side effects were noted during the follow-up period. Conclusions. in this small series of aphakic eyes with limited follow-up, ranibizumab by anterior chamber administration seems to be a safe and effective treatment for CNV secondary to pathologic myopia (PM), without any complications. Further studies to evaluate the safety and efficacy are justified. Keywords. Ranibizumab, safety, efficacy, myopic CNVs, aphakia, anterior chamber.